The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer

Annual Review of Medicine

Volumn 50, Issue , 1999, Pages 401-423

  Tsihlias, J ^a   Kapusta, L ^b   Slingerland, J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

cdk inhibitor; p15 p16 deletions; p21(Cip1); p27(Kip1); Prognostic factor

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; PROTEIN P21; PROTEIN P27;

BREAST CARCINOMA; CELL CYCLE; COLON CARCINOMA; GENE DELETION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; REVIEW; STOMACH CARCINOMA;

BREAST NEOPLASMS; CARCINOMA; CARRIER PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; COLONIC NEOPLASMS; COLORING AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; FEMALE; GENE DELETION; GENES, P16; GENES, TUMOR SUPPRESSOR; HOMOZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 0032980308     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.50.1.401     Document Type: Review

References (92)

1. 1. Solomon MJ. 1993. Activation of the various cyclin/cdc2 proteins. Curr. Opin Cell Biol. 5:180-86
2. 2. Morgan DO. 1995. Principles of Cdk regulation. Nature 374:131-34
3. 3. Sherr CJ. 1994. GI phase progression: cycling on cue. Cell 79:551-55
4. 4. Sherr CJ, Roberts JM. 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1149-63
5. 5. Reed SI, Bailly E, Dulic V, et al. 1994. G1 control in mammalian cells. J. Cell Sci. 18:69-73 (Suppl.)
6. 6. Murray AW. 1992. Creative blocks: cell cycle checkpoints and feedback controls. Nature 359:599-604
7. 7. Hartwell L. 1992. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71: 543-46
8. 8. Parry D, Bates S, Mann DJ, Peters G. 1995. Lack of cyclin D-cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J. 14: 503-11
9. 9. Sandhu C, Garbe J, Daksis J, et al. 1997. TGF-β stabilizes p15INK4B protein, increases p15INK4B/cdk4 complexes and inhibits cyclin D1/cdk4 association in human mammary epithelial cells. Mol. Cell Biol. 17:2458-67
10. 10. Cairns P, Mao L, Merlo A, et al. 1994. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415-17
11. 11. Cairns P, Polascik TJ, Eby Y, et al. 1995. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet. 11:210-12
12. 12. Hunter T, Pines J. 1994. Cyclins and cancer II: cyclin D and cdk inhibitors come of age. Cell 79:573-82
13. 13. Bates S, Peters G. 1995. Cyclin D1 as a cellular proto-oncogene. Sem. Cancer Biol 6:73-82
14. 14. Hannon GJ, Beach D. 1994.p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-61
15. 15. El-Deiry WS, Tokino T, Velculescu VE, et al. 1993. WAF1, a potential mediator of p53 tumor supression. Cell 75:817-25
16. 16. Noda A, Ning Y, Venable SF, et al. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211: 90-98
17. 1CIPl in muscle and other terminally differentiating cells. Science 267:1024-28
18. 18. Skapek SX, Rhee J, Spicer DB, Lassar AB. 1995. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267: 1022-24
19. 19. Halevy O, Novitch BG, Spicer DB, et al. 1995. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018-22
20. 20. Koff A, Ohtsuki M, Polyak K, et al. 1993. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science 260:536-39
21. Kipl, a cyclin-Cdk inhibitor, links transforming growth factor-b and contact inhibition to cell cycle arrest. Genes Dev. 8:9-22
22. Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66
23. 23. Slingerland JM, Hengst L, Pan C-H, et al. 1994. A novel inhibitor of cyclin-cdk activity detected in Transforming Growth Factor β-arrested epithelial cells. Mol. Cell Biol. 14:3683-94
24. 24. Hengst L, Dulic V, Slingerland J, et al. 1994. A cell cycle regulated inhibitor of cyclin dependant kinases. Proc. Natl. Acad. Sci. USA 91:5291-94
25. 25. Zhang H, Hannon G, Beach D. 1994. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8: 1759-58
26. Kipl Genes Dev 11:2335-46
27. Kipl and the timing of oligodendrocyte differentiation. EMBO J. 16:306-17
28. 28. Koyama H, Raines EW, Bornfeldt KE, et al. 1996. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors. Cell 87: 1069-78
29. Kipl. Cell 85:721-32
30. Kipl display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-20
31. Kipl-deficient mice. Cell 85:733-44
32. 32. Galaktionov K, Lee A, Eckstein J, et al. 1995. Cdc25 phosphatases as potential human oncogenes. Science 269:1575-77
33. 33. Keyomarsi K, Pardee AB. 1993. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc. Natl. Acad. Sci. USA 90:1112-16
34. 34. Musgrove EA, Hamilton JA, Lee CSL, et al. 1993. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol. 13:3577-87
35. 35. Dutta A, Chandra R, Leiter LM, Lester S. 1995. Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc. Natl. Acad. Sci. USA 92:5386-90
36. 36. Gillett C, Fantl V, Smith R, et al. 1994. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 54:1812-17
37. 37. Bartokova J, Lukas J, Muller H, et al. 1994. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer 57:353-61
38. 38. Bartokova J, Lukas J, Strauss M, Bartek J. 1994. Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J. Pathol. 172:237-45
39. 39. Buckley MF, Sweeney KJE, Hamilton JA, et al. 1993. Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-33
40. Kipl and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3: 222-25
41. 41. Nielsen N, Arnerlov C, Emdin S, Landberg G. 1996. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to estrogen receptor status. Br. J. Cancer 74:874-80
42. 42. Wang TC, Cardiff RD, Zukerberg L, et al. 1994. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-71
43. 43. Hinds PW, Dowdy SF, Eaton EN, et al. 1994. Function of a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. USA 91:709-13
44. 44. Lovee H, Sewing A, Lucibello FC, et al. 1994. Oncogenic activity of cyclin D1 revealed through cooperation with Haras: link between cell cycle control and malignant transformation. Oncogene 9: 323-26
45. 45. Bodrug SE, Warner BJ, Bath ML, et al. 1994. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with myc gene. EMBO J. 13:2124-30
46. 46. Hara E, Smith R, Parry D, et al. 1996. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell Biol. 16: 859-67
47. 47. Alcorta DA, Xiong Y, Phelps D, et al. 1996. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA 93:13742-47
48. 48. Serrano M, Lee H, Chin L, et al. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37
49. Kipl in human malignancies. Cancer Res. 55: 2266-69
50. Kipl: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumours. Cancer Res. 55:1211-14
51. Kipl gene to 12p13 and its analysis in luekemias. Cancer Res. 55:1206-10
52. Kipl) of cyclin-dependent kinase 4 activation. Cell 79:487-96
53. kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372:570-73
54. 54. Sherr JS. 1996. Cancer cell cycles. Science 274:1672-16 77
55. 55. Tan P, Cady B, Wanner M, et al. 1997. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 57:1259-63
56. Kipl protein: prognostic implications in primary breast cancer. Nat. Med. 3:227-30
57. Kipl protein in human prostate cancer correlates with tumor grade. Clin. Cancer Res. 3:2269-74
58. Kipl is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58:542-48
59. 59. Yang RM, Naitoh J, Murphy M, et al. 1998. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 159:941-45
60. 60. Loda M, Cukor B, Tam SW, et al. 1997. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3:231-34
61. 61. Mori M, Mimori K, Shiraishi T, et al. 1997. p27 expression and gastric carcinoma. Nat. Med. 3:5 93
62. 62. Esposito V, Baldi A, De Luca A, et al. 1997. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57: 3381-85
63. 63. Singh SP, Lipman J, Goldman H, et al. 1998. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 58:1730-35
64. 64. Thomas GV, Szigeti K, Murphy M, et al. 1998. Downregulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am. J. Pathol. In pre ss
65. Kipl in malignant melanoma: inverse correlation with disease free survival. Am. J. Path. 153: 305-12
66. 66. Wakasugi E, Kobayashi T, Tamaki Y, et al. 1997. p21 (waf1/cipl) and p53 protein expression in breast cancer. Am. J. Clin. Pathol. 107:684-91
67. 67. Jiang M, Shao Z-M, Wu J, et al. 1997. p21/waf1/cipl and mdm-2 expression in breast carcinoma patients as related to prognosis. Int. J. Cancer 74:529-34
68. 68. Barbareschi M, Caffo O, Doglioni C, et al. 1996. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br. J. Cancer 74: 208-15
69. 69. Johnson EA, Davidson AG, Hostetter RB, et al. 1996. The expression of Waf-1 in node-negative infiltrating ductal breast carcinoma. Proc. Am. Assoc. Cancer Res. 37:569
70. 70. Diab SG, Yu Y-Y, Hilsenbeck SG, et al. 1997. WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res. Treat. 43:99-103
71. 71. Meyer JS. 1977. Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Hum. Pathol. 8:67-81
72. 72. Ferguson DJP, Anderson TJ. 1981. Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast. Br. J. Cancer 44:177-81
73. 73. Moelandsmo GM, Holm R, Fodstad O, et al. 1996. The cyclin kinase inhibitor p21WAF/Cip in malignant melanoma: reduced expression in metastatic lesions. Am. J. Pathol. 149:1813-22
74. WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br. J. Cancer. 75: 1617-20
75. 75. Gomyo Y, Ikeda M, Osaki M, et al. 1997. Expression of p21 (waf1/cipl/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 79:2067-72
76. 76. Backe J, Gassel AM, Hauber K, et al. 1997. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int. J. Gynecol. Pathol. 16: 361-68
77. 77. Ito K, Sasano H, Matsunaga G, et al. 1997. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J. Pathol. 183:318-24
78. cipl/waf1 protein accumulations in head-and-neck cancer. Int. J. Cancer 74:383-89
79. 79. Pollak C, Hagemeijer A. 1987. Abnormalities of the short arm of chromosome 9 with partial loss of material in hematological disorders. Leukemia 1:541
80. 80. Olopade OL, Bohlander SK, Pomykala H, et al. 1992. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics 14:437
81. INK4b/MTS2in pediatric acute lymphoblastic leukemia. Blood 85:2321-30
82. 82. Kees UR, Burton PR, Lu C, Baker DL. 1997. Homozygous deletion of the p16/ MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood 89: 4161-66
83. INK4 gene inactivation in childhood acute lymphocytic leukemia. J. Clin. Oncol. 14:1512-20
84. 84. Zhou M, Gu L, Yeager AM, Findley HW. 1997. Incidence and clinical significance of cdkn2/MTS1/p16ink4A and MTS2/p15ink4b gene deletions in childhood acute lymphoblastic leukemia. Ped. Hematol. Oncol 14(2):141-50
85. 85. Diccianni MB, Batova A, Yu J, et al. 1997. Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. Leuk. Res. 21:549-58
86. 86. Rubnitz JE, Behm FG, Pui C-H, et al. 1997. Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St. Jude total therapy study XII. Leukemia 11:1201-6
87. 87. Takeuchi S, Bartram CR, Seriu T, et al. 1995. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/ INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 86:755-60
88. 88. Garcia-Sanz R, Gonzalez M, Vargas M, et al. 1997. Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas. Leukemia 11:1915-20
89. INK4 expression in non-small cell lung carcinoma. Cancer 80:389-95
90. 90. Kratzke RA, Greatens TM, Rubins JB, et al. 1996. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res. 56:3415-20
91. 91. Straume O, Akslen LA. 1997. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int. J. Cancer 74: 535-39
92. 92. Dong Y, Walsh MD, McGuckin MA, et al. 1997. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int. J. Cancer 74: 57-63